



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

April 19, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – April 17 2021

TOTAL Cases Reported Since 1/22/20

31,444,706

NEW Cases Reported to CDC on 4/17/21

60,947

Change in 7-Day Case Average

+1.1%


Current 7-Day Case Average (4/11/21 - 4/17/21)

67,443

Prior 7-Day Case Average (4/4/21 - 4/10/21)

66,702

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	315,006 (1/8/21)	249,861 (1/11/21)
2nd Peak	75,534 (7/17/20)	67,390 (7/21/20)
1st Peak	42,533 (4/6/20)	31,944 (4/12/20)



*7-day averages exclude historical cases reported retroactively by states



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – April 16, 2021

Patients Currently Hospitalized with COVID on 4/16/21

34,223

New Admissions on 4/16/21

5,317

Peak in New Admissions (1/5/21)

17,988

Change in 7-Day Average of New Admissions


+0.2%

Current 7-Day Average of New Admissions (4/10/21 - 4/16/21)

5,459

Prior 7-Day Average of New Admissions (4/3/21 - 4/9/21)

5,449



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – April 17, 2021

TOTAL Deaths Reported Since 1/22/2020

563,980

NEW Deaths Reported to CDC on 4/17/21

694

Change in 7-Day Death Average

+2.1%

Current 7-Day Death Average (4/11/21 - 4/17/21)


695

Prior 7-Day Death Average (4/4/21 - 4/10/21)

681

Forecasted Total Deaths by 5/8/21

574,000 to 598,000



COVID-19 Vaccination, United States

December 14, 2020 – April 18, 2021

Total Doses Delivered (12/14/20 - 4/18/21)

264,505,725

Total Doses Administered (12/14/20 - 4/18/21)

209,406,814

People Receiving ≥ 1 Dose (% Population)


131,247,546 (39.5%)

People Fully Vaccinated (% Population)

84,263,408 (25.4%)

Percent of People ≥ 65 Years Fully Vaccinated

65.9%




● Daily Doses Administered — 7-Day Average of Doses Administered

The four-day lag in reporting for which data is not complete is indicated by grey bars.





WEAR A MASK



STAY 6 FEET APART



AVOID CROWDS



AVOID TRAVEL

April 19, 2021



**All those eligible for COVID-19
vaccines can get vaccinated**



COVID-19 Vaccines are:

- **Efficacious in clinical trials**
- **Effective in real-world settings**
- **Safe**



COVID-19 Vaccines are:

- Efficacious in clinical trials**
- Effective in real-world settings**
- Safe**



Pfizer/BioNTech Vaccine



Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

FP Polack et al. for the
C4591001 Clinical Trial Group

■ **Efficacy: 95%**

Moderna Vaccine



Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

LR Baden et al. for the
COVE Study Group

■ **Efficacy: 94.1%**

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Efficacy:

- **66% overall vs. moderate-to-severe COVID-19**
 - 72% in U.S.
 - 66% in Latin America
 - 57% in South Africa
- **85% vs. severe disease across all regions studied**
- **Protection generally consistent across all age groups**

COVID-19 Vaccines are:

■ **Efficacious in clinical trials**

■ **Effective in real-world settings**

■ **Safe**



“Real World” Vaccine Effectiveness Studies



Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

W Daniel, DK Podolsky et al.

- 23,234 employees of University of Texas Southwestern Medical Center, Dallas, TX; vaccination program initiated 12/15/2020
- 0.05% infection rate among fully vaccinated employees



Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™

April 2, 2021

Morbidity and Mortality Weekly Report (MMWR) Volume 70, Number 13

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

- Prospective study; n=3,950
- mRNA vaccine effectiveness of full immunization (≥ 14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; 80% after one dose
- 3 PCR-confirmed infections occurred during 78,902 person-days with full immunization (0.04/1,000 person-days)





The
New England
Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

VOLUME 384

APRIL 15, 2021

NUMBER 15

BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting

LN Dagan, RD Balicer et al.

- 600,000 newly vaccinated people and 600,000 matched controls in Israel

Vaccine effectiveness

7 or more days after 2nd dose

Documented infection

92%

Symptomatic COVID-19


94%

Severe disease

92%



Effect of Robust COVID-19 Vaccination Effort in Israel, Where B.1.1.7 Predominates



COVID-19 Vaccines are:

- **Efficacious in clinical trials**
- **Effective in real-world settings**
- **Safe**



Ensuring COVID-19 Vaccine Safety in the U.S.

- **Clinical trials**
- **Expanded safety monitoring systems**
 - CDC: V-safe
 - CDC: National Healthcare Safety Network (NHSN)
 - FDA: Other large insurer/payer databases
- **Other safety monitoring systems**
 - CDC and FDA: Vaccine Adverse Event Reporting System (VAERS)
 - CDC: Vaccine Safety Datalink (VSD)
 - CDC: Clinical Immunization Safety Assessment (CISA) Project
 - FDA and the Centers for Medicare and Medicaid Services: Medicare data
 - FDA: Biologics Effectiveness and Safety System (BEST)
 - FDA: Sentinel Initiative
 - DoD, FDA systems

Source: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/reporting-systems.html>



Normalcy in America



Vaccines





THE WHITE HOUSE
WASHINGTON

WH.GOV